Skip to main content

Table 1 Character of included studies

From: A pooled analysis of mesenchymal stem cell-based therapy for liver disease

Study

Country

Study design

Patient populations

Sample size (MSC/control)

Average age (MSC/control)

Male (%)

Cell type

Delivery route

Times of injection

Dosage of MSCs/ml

Number of MSCs

Maximum follow-up (months)

Y. Du, 2011 [37]

China

nRCT

Decompensated liver cirrhosis

25/25

53

82.0%

UC-MSCs

Artery

Multiple

1

(0.1–1.0) × 108 cells

2

L. Peng, 2011 [38]

China

nRCT

Liver failure

6/15

42.19/42.22

94.3%

B-MSCs

Artery

Single

10

1 × 107 cells

12

Amer ME, 2011 [27]

Egypt

RCT

End-stage liver failure

20/20

50.5/50.0

82.5%

B-MSCs

Intrasplenic vs intrahepatic

Single

5

NR

6

H. Lin, 2012 [24, 25]

China

RCT

Decompensated liver cirrhosis

38/16

47/48

90.7%

UC-MSCs

Vein

Multiple

60

(0.5–1.0) × 106/kg

12

Z. Zhang, 2012 [28]

China

RCT

Decompensated liver cirrhosis

30/15

48/47

88.9%

UC-MSCs

Vein

Multiple

NR

0.5 × 106/kg

12

El-Ansary M, 2012 [39]

Egypt

nRCT

Advanced liver cirrhosis

15/10

48/51.6

76.0%

B-MSCs

Vein

Single

NR

1 × 106/kg

6

J. Yu, 2012 [40]

China

nRCT

End-stage liver failure

13/22

43.46/47.45

82.9%

B-MSCs

Vein

Single

100

5 × 106 cells

1

Y. Zhang, 2012 [29]

China

RCT

Decompensated liver cirrhosis

12/18

48.63/49.86

70.0%

UC-MSCs

Artery

Single

10

≥ 2 × 107 cells

3

S. Ouyang, 2013 [41]

China

nRCT

Decompensated liver cirrhosis

33/34

53.1/55.2

83.6%

B-MSCs

Artery

Single

5

(3–5) × 106 cells

6

M. Zhu, 2013[42]

China

nRCT

Decompensated liver cirrhosis

22/20

48.5/49.2

81.0%

UC-MSCs

Vein

Multiple

100

1 × 108 cells

2

B. Liu, 2013[43]

China

nRCT

Acute-on-chronic liver failure

16/19

38.7

80.0%

UC-MSCs

Vein vs artery

Single

NR

> 5 × 107 cells

3

Q. Wang, 2013 [30]

China

RCT

Chronic liver failure

9/9

50.71 (median)

85.7%

UC-MSCs

Vein

Multiple

NR

(1.2–6.2) × 107/ml

4

L. Xu, 2014 [31]

China

RCT

Liver cirrhosis

20/19

44/45

61.5%

B-MSCs

Artery

Single

20

4 × 107 cells

6

Mohamadnejad M, 2013 [11]

Iran

RCT

Decompensated liver cirrhosis

14/11

43.1/34.6

52.0%

B-MSCs

Vein

Single

100

1.95 × 108 cells

12

H. Salama, 2014 [32]

Egypt

RCT

End-stage liver disease

20/20

50.27/50.9

82.5%

B-MSCs

Vein

Single

100

1 × 106/kg

6

L. Zhuang, 2014 [44]

China

nRCT

Liver cirrhosis

29/35

55/56

78.1%

UC-MSCs

Portal vein

Single

NR

0.5 × 108 cells

6

H. He, 2015 [45]

China

nRCT

Acute-on-chronic liver failure

46/54

43.8/44.5

89.0%

UC-MSCs

Vein

Multiple

100

1 × 105/kg

3

H. Luo, 2015 [46]

China

nRCT

Decompensated liver cirrhosis

50/46

43/44

88.5%

UC-MSCs

Vein

Multiple

100

NR

3

L. Tong, 2015 [47]

China

nRCT

Decompensated liver cirrhosis

20/20

56.4/56

55.0%

UC-MSCs

Vein

Multiple

100

(2–4) × 109 cells

6

Y. Li, 2015 [33]

China

RCT

Acute-on-chronic liver failure

31/27

41.6/43.1

89.7%

UC-MSCs

Vein

Multiple

60

(0.5–1.0) × 106/kg

12

D. Zhang, 2016 [36]

China

RCT

Hepatic fibrosis

30/30

30.98/32.1

55.0%

B-MSCs

Vein

Multiple

2

6 × l06 cells

3

K.T. Suk, 2017 [34]

South Korea

RCT

Liver cirrhosis

37/18

53.7/53.7

89.1%

B-MSCs

Artery

Single vs multiple

10

5 × 107 cells

12

B.-L. Lin, 2017 [35]

China

RCT

Acute-on-chronic liver failure

56/54

40/42.8

94.5%

B-MSCs

Vein

Multiple

10

1 × 103 to 1 × 105/kg

6

J. Shen, 2015 [26]a

China

nRCT

Decompensated liver cirrhosis

28/28

42.4

94.6%

B-MSCs

Artery

Single

NR

(1.7 ± 0.4) × 107/ml

36

Kantarcioʇlu M, 2015 [62]

Turkey

Uncontrolled

Liver cirrhosis

12

39

58.3%

B-MSCs

Vein

Single

NR

1 × 106/kg

12

M. El-Ansary, 2010 [48]

Egypt

Uncontrolled

Chronic liver failure

12

49.67

75.0%

B-MSCs

Intrasplenic vs vein

Single

5

1 × 106 cells

6

J. Chen, 2015 [49]

China

Uncontrolled

Decompensated liver cirrhosis

27

45.22

63.0%

UC-MSCs

Vein

Multiple

20

≥ 2 × 107 cells

3

Z. Wang, 2013 [50]

China

Uncontrolled

Liver cirrhosis

10

53.7

90.0%

B-MSCs

Artery

Single

NR

1 × 106/kg

3

L. Wang, 2013 [51]

China

Uncontrolled

Liver cirrhosis

10

49

10.0%

B-MSCs

Vein

Single

20

(0.5–1.0) × 106/kg

12

Li. Wang, 2013 [52]

China

Uncontrolled

Decompensated liver cirrhosis

23

57.3

69.6%

UC-MSCs

Both vein and artery

Multiple

50

NR

12

H. Zhang, 2013 [53]

China

Uncontrolled

Decompensated liver cirrhosis

25

18–72 (range)

84.0%

B-MSCs

Artery

Single

3-5

(3–5) × 107 cells

3

J. Li, 2012 [54]

China

Uncontrolled

Liver cirrhosis

87

46.9

65.5%

B-MSCs

Artery

Single

NR

1 × 106 /kg

2

J. Wang, 2012 [55]

China

Uncontrolled

Decompensated liver cirrhosis

21

46

90.5%

UC-MSCs

Vein

Single

30

(0.6–1.5) × 109 cells

3

J. Guo, 2012 [56]

China

Uncontrolled

Decompensated liver cirrhosis

15

32

66.7%

UC-MSCs

Both vein and artery

Multiple

20

(2–6) × 107 cells

3

B. Zhou, 2011 [57]

China

Uncontrolled

Decompensated liver cirrhosis

60

57.97

58.3%

UC-MSCs

Artery

Single

40

2 × 107 cells

3

H. Yu, 2011 [58]

China

Uncontrolled

Decompensated liver cirrhosis

10

6.78

100.0%

UC-MSCs

Artery

Single

NR

2 × 107 cells

6

D. Niu, 2011 [59]

China

Uncontrolled

Autoimmune liver disease

7

53–68 (range)

28.6%

UC-MSCs

Vein

Multiple

NR

8 × 107 cells

12

H. Chen, 2011 [60]

China

Uncontrolled

Chronic liver failure

20

45.2

70.0%

B-MSCs

Artery

Single

50

≥ 1 × 109 cells

3

X. Jin, 2012 [61]

China

Uncontrolled

Decompensated liver cirrhosis

24

45.6

83.3%

UC-MSCs

Vein

Single

10

2 × 107 cells

3

  1. a This nRCT was regarded as an uncontrolled trial because the control group data could not be extracted
  2. Artery hepatic artery, B-MSC bone marrow-derived mesenchymal stem cell, MSC mesenchymal stem cell, NR not reported, nRCT nonrandomized controlled trial, RCT randomized controlled trial, UC-MSC umbilical cord-derived mesenchymal stem cell, Vein peripheral vein,